Secondary Progressive Multiple Sclerosis (SPMS) Clinical Trial

Secondary progressive multiple sclerosis (SPMS) is a later stage of the chronic disease multiple sclerosis MS.

Most people with MS start out with a clinical course characterized by episodes or attacks (relapses) of neurologic dysfunction, which occur over many years. This is called the relapsing-remitting phase. Symptoms of such relapses include vision loss or double vision, numbness/tingling in the extremities, muscle weakness, slurred speech, difficulty with coordination, and bladder dysfunction. Unlike the first phases of MS, SPMS gets steadily worse and relapses are no longer likely. SPMS can be difficult to diagnose.

Limited approved MS and SPMS therapies are currently available. Meridian is conducting a Phase III clinical trial for an investigational medication for people with SPMS.

Eligible participants…

• Must be age 18 to 60
• Must be diagnosed with SPMS
• Must have an absence of clinical relapses for 24 months
• Must have documented evidence of 12 months of disability progression
• May receive compensation for time and travel
• Do not need insurance to join this study

For more information, complete the form on this page. After you submit your information, a Meridian enrollment specialist will call you to talk about the study. There is no obligation to join — you can decide if the study is right for you.

You can also talk to a Meridian enrollment specialist about this study by calling (912) 354-7676.